Hospital
Roper ST. Francis Mount Pleasant Hospital
Roper ST. Francis Mount Pleasant Hospital was paid $2.47M by Medicaid between Jan 2018 and Dec 2024, across 69 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoROPER ST. FRANCIS MOUNT PLEASANT HOSPITAL
MT PLEASANT, SC 29466
MT PLEASANT, SC 29466
33aNPI1255645644assigned 07/28/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.47M
24GClaims63,797
24DCodes billed69
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#58 of 115
Median peer was paid$2.47M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,658 | $217K | |
| 2019 | 8,813 | $200K | |
| 2020 | 6,412 | $176K | |
| 2021 | 7,758 | $249K | |
| 2022 | 9,735 | $583K | |
| 2023 | 12,137 | $610K | |
| 2024incomplete | 11,284 | $431K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 7,064 | 6,553 | $469K |
| 80048 | Basic metabolic panel (calcium, ionized) | 10% | 3,760 | 3,273 | $250K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 7.9% | 1,180 | 1,075 | $195K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.8% | 2,724 | 2,463 | $193K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.3% | 1,371 | 1,313 | $180K |
| 81025 | 7.3% | 2,715 | 2,527 | $179K | |
| 80053 | Comprehensive metabolic panel | 6.5% | 2,823 | 2,508 | $160K |
| 81003 | 5.8% | 2,853 | 2,679 | $143K | |
| 36415 | Collection of venous blood by venipuncture | 3.4% | 952 | 853 | $83K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.3% | 1,508 | 1,260 | $82K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 907 | 854 | $80K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.0% | 4,695 | 4,289 | $73K |
57 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.6% | 554 | $39K |
| 81001 | 1.4% | 1,398 | $33K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 521 | $26K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 333 | $25K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 674 | $24K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 68 | $23K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,144 | $23K |
| 99285 | Emergency room visit (most serious) | <1% | 2,325 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,550 | $20K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 65 | $19K |
| J3490 | Unclassified drugs | <1% | 137 | $16K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 163 | $15K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 735 | $15K |
| 84484 | <1% | 1,650 | $11K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 44 | $10K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 90 | $9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 45 | $7K |
| 85027 | <1% | 1,710 | $6K | |
| 87430 | <1% | 42 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 193 | $5K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 75 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 58 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 882 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,578 | $3K |
| 87428 | <1% | 14 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,547 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,765 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 47 | $1K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 31 | $926.75 |
| A9270 | Non-covered item or service | <1% | 914 | $706.93 |
| 76642 | <1% | 18 | $608.81 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $515.18 |
| 59025 | Fetal non-stress test | <1% | 12 | $458.97 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 34 | $428.39 |
| 80076 | <1% | 583 | $158.89 | |
| 80061 | Lipid panel | <1% | 57 | $58.63 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 221 | $49.04 |
| 83605 | <1% | 395 | $20.40 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 899 | $9.96 |
| 87040 | <1% | 30 | $9.10 | |
| 83690 | <1% | 1,505 | $5.75 | |
| 85610 | 0% | 48 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 104 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 556 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 154 | $0.00 |
| 83880 | 0% | 75 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 430 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 16 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 229 | $0.00 |
| 83735 | 0% | 572 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 743 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 16 | $0.00 |
| 85379 | 0% | 52 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 16 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 45 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 55 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (VP REIMBURSEMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.